Trial Profile
Comparison of HIV RNA Suppression Produced by Triple Regimens Containing Either Didanosine Enteric Coated or Didanosine Formulations Each Administered Once Daily
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Didanosine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 08 Jun 2009 New trial record.